Skip to content
Medical Health Aged Care, Mental Health

Leading research program targets the biology of eating disorders

Monash University 3 mins read

A revolutionary Monash University-led eating disorder research program launched tonight (Sunday 11 June) will target biological causes and possible new treatments including novel drugs, brain stimulation and hormones.

The world class Li Transformative Hub for Research in Eating Disorders (THRED) will be coordinated through Monash University’s HER Centre Australia, which was launched in 2022 to consolidate and expand research into and treatment of women’s mental illness. 

Researchers from the HER Centre and the Department of Neuroscience in Monash’s Central Clinical School will work collaboratively on the disorders.

An estimated one million Australians, or four per cent, live with an eating disorder such as anorexia nervosa, bulimia nervosa, and binge eating disorder. The THRED program will have three key pillars: delivering new, effective treatments, enhancing current treatments and uncovering biological causes.


It was made possible by a generous donation by THRED’s Founding Patrons, Melbourne Symphony Orchestra chair and former professional violinist David Li AM and his pianist wife, Angela Li. They provided seed funding and HER Centre Australia and the Central Clinical School will align its philanthropic vision and goals with generating additional funding to achieve THRED’s full potential.


HER Centre Australia Director Professor Jayashri Kulkarni AM said as the incidence of eating disorders (EDs) continued to rise in the wake of Covid-19, a new approach was needed. She said most treatments focussed on talking therapies, with varying success, and effective biological treatments had not been developed.

“Over the past 60 years there has not been any real change in how treatments for eating disorders, which cover a spectrum ranging from various disordered patterns of eating to anorexia nervosa, have been delivered,” Professor Kulkarni said.


“We need a new approach. We want to provide a better understanding of why EDs occur and how to treat them from a biological perspective. We will do this by conducting clinical trials that will investigate possible treatments. These trials will be informed by investigation into the biological abnormalities that underpin eating disorders” 

THRED will conduct clinical trials of new treatment approaches for serious eating disorders, and hopefully deliver more effective treatment options. 

Expected to start in the second half of 2023, its clinical trials will assess brain stimulation, hormonal manipulation and novel drug therapies as well as developing new treatments as they are generated based on their own and other research findings from Australia and around the world. 

To this end, discovery science uncovering the role of genes and proteins in a personalised medicine approach will be undertaken and linking all this will be novel artificial intelligence driven smartphone technologies to deliver personalised care to people experiencing an eating disorder. 

Professor Kulkarni said eating disorders could develop due to biological changes related to genes, RNA, and proteins, yet not much had been invested in developing treatments that targeted brain biology and/or biological factors. She said a holistic approach was needed.


“For too long, eating disorders have been surrounded by ignorance about their cause and stigma that often assigns blame to the person with the ED ‘if only she would eat … the problem would go away’,” Professor Kulkarni said.


“It’s not that simple. These are complex conditions that require multi-faceted solutions. Psychotherapy is important but does not encompass the big picture, or the possibility of biological causes. 


“The impact of eating disorders also worsened during Covid, with some people eating too much and others developing anorexia. We have a condition that has a high mortality and a very high morbidity but the only treatments available are ‘talking therapies’ that haven’t provided patients with the treatment they deserve.”


Eventually, THRED hopes to move into a second phase of research investigating biomarkers that could help define ED subtypes and pave the way for new treatments.


“This program won’t be a ‘silver bullet’ for eating disorders, which are notoriously difficult to treat,” Professor Kulkarni said. “But we hope our focus on the biology will result in improved treatments that will make a real difference. 


“There have been very few biological eating disorder treatment trials, and what has been done has been very patchy. We believe this program is unique in Australia and possibly a world-first in terms of its combination of neurological trials in a clinical setting, with a focus on brain stimulation, hormones and new medications, coupled with discovery sciences approaches to discover root causes.”

The Dean of Monash University’s Sub-Faculty of Translational Medicine and Public Health, Professor Stephen Jane, emphasised the importance of the initiative.

“A new lens for examining the causes of eating disorders and for the development of new treatment paradigms is desperately needed – the combination of discovery science coupled with clinical trials represents a unique approach that we believe will positively re-sculpt the landscape for patients with eating disorders,” he said.

For media enquiries please contact:


Monash University

Cheryl Critchley - Communications Manager (medical)

T: +61 (0) 418 312 596


For more Monash media stories, visit our news and events site  

For general media enquiries please contact:
Monash Media
T: +61 (0) 3 9903 4840




More from this category

  • Medical Health Aged Care
  • 04/12/2023
  • 09:52

RINVOQ® (upadacitinib) now reimbursed for Australians living with Severe Crohn’s disease1

RINVOQ®, a once daily tablet, has become available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients living with severe active Crohn’s disease (CD)1,2 It’s the first new molecule for CD to be funded by the Government in seven years1,3 Australia has one of the high rates in the world, impacting many in their 20s to 30s-6 Currently there is no cure for CD and severity of the disease is on the rise due to environmental & dietary factors7,8 SYDNEY, AUSTRALIA, 4 December 2023 – AbbVie (NYSE: ABBV), is pleased to announce RINVOQ® (upadacitinib), a once daily tablet, has been…

  • Medical Health Aged Care
  • 04/12/2023
  • 09:47
For immediate release - December, 4 2023

Survey reveals what’s standing in the way of good health

Aussies are being urged to prioritise their health and wellbeing with research revealing more than 40 per cent feel cost or time pressures are the main barrier standing in their way. With the end of year approaching, Australians are being encouraged to make the most from their health insurance and book any medical appointments they might have forgotten or missed in 2023. The Bupa Pulse Check study also revealed that of the 38 per cent of Australians who say they’re struggling to maintain their health and wellbeing, 50 per cent feel cost was a barrier with the survey also showing…

  • Employment Relations, Mental Health
  • 04/12/2023
  • 06:31
RMIT University

5 ways to avoid burnout before the break

Feel like you have a marathon to run before the end of year, when you barely have energy to run 100 metres? Management experts say burnout can be easily avoided if you take charge of your own wellbeing. Asanka Gunasekara, Lecturer, Human Resource Management/People Analytics Melissa Wheeler, Senior Lecturer, Business Administration Topics: burnout, work-life integration, wellbeing We often feel exhausted towards the end of year as we are working tirelessly at work while social commitments and Christmas tasks expand. Burnout is the feeling of exhaustion, disengagement, ineffectiveness, cynicism, and a sense of moving with no motivation or meaning. It has negative…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.